Sangamo Therapeutics (SGMOQ) Gains from Investment Securities (2014 - 2015)
Sangamo Therapeutics (SGMOQ) posted Gains from Investment Securities of -$1.8 million for Q1 2015, down 1900.0% on a QoQ basis from $100000.0 in Q4 2014, and down 3700.0% year-over-year from $50000.0 in Q1 2014.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Gains from Investment Securities (2014 - 2015) Analysis & Trends
Sangamo Therapeutics has reported Gains from Investment Securities for 2 years, with the latest figure at -$1.8 million in Q1 2015.
- On a quarterly basis, Gains from Investment Securities fell 3700.0% year-over-year to -$1.8 million in Q1 2015; TTM through Dec 2015 was -$1.8 million, a 882.61% decrease from a year earlier, with the FY2015 full-year figure at -$1.8 million, down 882.61% from the prior year.
- Gains from Investment Securities was -$1.8 million for Q1 2015 at Sangamo Therapeutics, down from $100000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $100000.0 in Q4 2014, with the low at -$1.8 million in Q1 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.28 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.54 Bn | 251.87 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2015 | -1.80 Mn |
| Dec 31, 2014 | 100,000.00 |
| Sep 30, 2014 | 50,000.00 |
| Jun 30, 2014 | 30,000.00 |
| Mar 31, 2014 | 50,000.00 |